Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by BadBlood01on Mar 10, 2021 10:54am

155 Views

Post# 32762443

Wired Guide to Cannabis

Sponsored Post Are you looking for more widely used and accepted medicinal health benefits that could be a start of your potential business venture? Check this out and be thrilled!

For thousands of years, humans have used the stuff as medicine or to travel on spiritual quests. The twisty-turny journey of cannabis has landed us back at a central truth. It’s indeed a powerful medicine that could treat what ails the human body.

Seems like scientists have proven cannabis could treat a range of ills and that it’s much safer than alcohol. Check disclaimer on profile and landing page.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario